Navigation Links
Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Date:3/13/2013

Rensselaer, NY (PRWEB) March 13, 2013

The Shingo Prize for Operational Excellence, part of the Jon M. Huntsman School of Business at Utah State University, has selected the Industrial Operations and Product Supply (IOPS) group of Regeneron Pharmaceuticals, Inc. as a recipient of the Shingo Bronze Medallion.

“Receipt of the Shingo Bronze Medallion signifies an organization’s strong use of tools and techniques for business improvement,” said Robert Miller, executive director of The Shingo Prize. “Those organizations that receive the Bronze Medallion are working to develop effective systems to create continuity and consistency throughout the business entity and are on their way to true operational excellence.”

Regeneron purchased the Rensselaer site in 1994 for the purpose of large-scale manufacturing of protein-based pharmaceuticals (biologics). In 2007, Regeneron entered into a collaborative effort with the global healthcare company, Sanofi, to discover and develop antibodies using the Regeneron VelocImmune™ technology and to advance several of these drug candidates into clinical development each year. The IOPS plant at Rensselaer was tasked with increasing its manufacturing output from one or two products to 15-30 bulk products and over 100 final product forms in less than five years. In order to successfully meet the requirements, the Rensselaer site had to respond with significant operations modifications and improvements. It now has the ability to produce as many as five different drug candidates simultaneously or more than 20 in a single year, placing it among the top 15 biopharmaceutical facilities worldwide in terms of production capacity.

“As I reflect back on the last six years, I can’t help but marvel at our progress,” said Daniel P. Van Plew, senior vice president and general manager of Industrial Operations and Product Supply. “Being recognized for our efforts is for sure exciting, but not as exciting as watching this journey continue to unfold a little more each day.”

Through its operations initiatives, the IOPS group at Rensselaer has experienced, among other achievements, a 200% increase in labor productivity, a 92% decrease in product changeover time and a more than 800% increase in the number of product forms manufactured.

Regeneron’s IOPS group will receive the Shingo Bronze Medallion at the Awards Ceremony and Gala during the 25th Annual Shingo Prize International Conference, May 6-10, 2013 in Provo, Utah. The awards gala is the conclusion to this four-day event featuring a selection of workshops, plant tours, keynote speakers and breakout sessions designed to provide ongoing knowledge, insights and experience for organizations in their pursuit of operational excellence.

“In providing recognition, The Shingo Prize invites organizations to challenge early in their implementation of improvement efforts,” Miller said. “Doing so provides them valuable feedback to help accelerate their implementation. By understanding the principles we teach, organizations can begin to proactively change their culture. Culture is the key to sustainable operational excellence.”

About The Shingo Prize
The Shingo Prize for Operational Excellence is named after Japanese industrial engineer Shigeo Shingo. Dr. Shingo distinguished himself as one of the world’s thought leaders in concepts, management systems and improvement techniques that have become known as the Toyota Business System. Drawing from Dr. Shingo’s teachings, The Shingo Prize helps companies and organizations increase their efficiency and effectiveness by developing cultures that better tap the talents of their employees. It also awards and recognizes organizations that demonstrate exceptional results from applying its philosophy. Those interested in more information or in registering to attend the 25th Annual International Conference may visit http://www.shingoprize.org.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma. Those interested in more information about the company may visit http://www.regeneron.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10524606.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Introducing a New, Easy Way for Industrial Businesses to Join the Online Conversation
6. Global Markets for Enzymes in Industrial Applications
7. Global Markets for Enzymes in Industrial Applications -- Focus on Europe
8. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
9. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
10. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
11. Biomass characterization technology research highlighted in Industrial Biotechnology journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , ... from around the world, was today awarded the "Best Science & Technology Social ... on merit and decided upon by a dedicated team of researchers and analysts. ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
Breaking Biology Technology:
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/12/2017)... -- New research undertaken by Fit Small Business has ... were simply asked which office technology had they not used ... issue.  Insights on what will be key features ... and industry leaders including Penelope Trunk , Martin ... Some of these findings included; ...
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
Breaking Biology News(10 mins):